Scinai Immunotherapeutics Receives Nasdaq Minimum Bid Price Delisting Warning

summarizeSummary

Scinai Immunotherapeutics received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance.

check_boxKey Events

• Nasdaq Minimum Bid Price Non-Compliance

  Scinai Immunotherapeutics Ltd. received a notification from Nasdaq on March 12, 2026, indicating non-compliance with Listing Rule 5550(a)(2) because its American Depositary Shares (ADSs) traded below $1.00 for 30 consecutive business days.

• 180-Day Compliance Period Granted

  The company has been granted an initial 180-calendar day period, until September 8, 2026, to regain compliance. This requires the closing bid price of its ADSs to be at least $1.00 for a minimum of ten consecutive business days.

• No Immediate Effect on Listing

  The notification does not have an immediate impact on the listing or trading of the company's ADSs on the Nasdaq Capital Market.

• Company to Evaluate Options

  Scinai Immunotherapeutics stated it will continue to monitor its ADS closing bid price and evaluate available options to regain compliance with the Nasdaq minimum bid price requirement.

auto_awesomeAnalysis

Scinai Immunotherapeutics has received a formal notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its stock has traded below $1.00 for 30 consecutive business days. While there is an initial 180-day compliance period, this is a significant concern for a micro-cap company like Scinai. Failure to regain compliance could lead to delisting, severely impacting liquidity and investor confidence. The company will likely need to consider options such as a reverse stock split to boost its share price above the $1.00 threshold before the September 8, 2026 deadline.